Risankizumab Safe, Effective at 52 Weeks for Psoriatic Arthritis
Long-term benefits seen in patients with inadequate response/intolerance to biologic or conventional disease-modifying antirheumatic drugs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.